Skip to main content
    G

    GeneDx Holdings Corp. (WGS)

    Official site

    HEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ

    $51.02
    -1.35 (-2.58%)

    Market Cap: $1.57B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    GeneDx Holdings Corp. (WGS) Earnings: Report Dates and Results

    Updated Nov 9, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    GeneDx Holdings (WGS) is confirmed to report earnings on Feb 22, 2027, after the close. In the quarter ended Sep 30, 2026, GeneDx Holdings reported EPS of $0.28, above the $0.07 estimate. It beat the EPS estimate in 7 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    67%(14/21)
    Avg Surprise
    +43.76%
    Streak
    2 Q

    Upcoming Estimates

    Reports Feb 22, 2027 after closePeriod ending Dec 31, 2026
    EPS Consensus$0.41
    Range$0.37 - $0.53
    9 analysts
    Revenue Consensus
    $137.43M
    Range$130.14M - $149.52M
    9 analysts
    Reports May 3, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus-$0.01
    Range-$0.16 - $0.10
    3 analysts
    EPS Revisions
    2
    2
    30d
    EPS Estimate DriftChange to current
    90d ago$0.06-110.4%
    60d ago$0.06-110.4%
    30d ago$0.04-116.8%
    7d ago$0.04-116.8%
    Current-$0.01
    Revenue Consensus
    $122.87M
    Range$115.30M - $130.70M
    6 analysts

    Next Report

    WGS has a confirmed report date of Feb 22, 2027, after the close. Analysts' consensus for the quarter ending Dec 31, 2026 is 192.9% above the $0.14 reported for the quarter ended Dec 31, 2025.

    WGS Earnings Call

    The latest WGS earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 21 quarters below that had an estimate, WGS beat 14 and missed 7. Revenue for the quarter ended Sep 30, 2026 was $123.10M, up 5.4% from $116.74M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$0.28$0.07$0.07 - $0.08+300.00%Beat-42.9%71 up, 7 downNov 9, 2026$123.10M
    Jun 30, 2026$0.01-$0.19-$0.30 - -$0.16+105.26%Beat-98.0%80 up, 6 downAug 3, 2026$114.44M
    Mar 31, 2026-$0.28-$0.05-$0.08 - $0.03-465.66%Miss-203.7%72 up, 2 downMay 4, 2026$102.25M
    Dec 31, 2025$0.14$0.12$0.01 - $0.23+16.67%Beat-78.0%73 up, 0 downFeb 23, 2026$120.99M
    Sep 30, 2025$0.49$0.42$0.28 - $0.55+16.67%Beat+1125.0%70 up, 1 downOct 28, 2025$116.74M
    Jun 30, 2025$0.50$0.11$0.08 - $0.14+354.55%BeatN/A51 up, 2 downJul 29, 2025$102.69M
    Mar 31, 2025$0.27$0.09$0.06 - $0.11+200.00%BeatN/A30 up, 1 downApr 30, 2025$87.11M
    Dec 31, 2024$0.64$0.10$0.03 - $0.20+515.00%BeatN/A30 up, 0 downFeb 18, 2025$95.64M
    Sep 30, 2024$0.04-$0.21-$0.27 - -$0.16+119.05%BeatN/A40 up, 0 downOct 29, 2024$76.87M
    Jun 30, 2024-$0.10-$0.30-$0.32 - -$0.26+66.67%BeatN/A30 up, 0 downJul 30, 2024$70.51M
    Mar 31, 2024-$0.33-$0.67-$0.75 - -$0.57+50.75%BeatN/A31 up, 0 downApr 29, 2024$62.42M
    Dec 31, 2023-$0.69-$0.75-$0.99 - -$0.60+8.00%BeatN/A30 up, 0 downFeb 20, 2024$57.42M
    Sep 30, 2023-$0.82-$1.31-$1.46 - -$1.18+37.40%BeatN/A30 up, 1 downOct 30, 2023$53.30M
    Jun 30, 2023-$1.77-$1.31-$1.47 - -$1.02-35.11%MissN/A30 up, 0 downAug 8, 2023$48.71M
    Mar 31, 2023-$2.90-$1.48-$3.96 - -$0.80-95.95%MissN/A30 up, 0 downMay 9, 2023$43.14M
    Dec 31, 2022-$0.25-$0.16-$0.19 - -$0.13-56.25%MissN/A30 up, 0 downMar 14, 2023$61.35M
    Sep 30, 2022-$6.65-$5.28N/A-25.95%MissN/AN/AN/ANov 14, 2022$83.23M
    Jun 30, 2022-$7.12-$5.61N/A-26.92%MissN/AN/AN/AAug 15, 2022$36.17M
    Mar 31, 2022-$8.84-$9.24N/A+4.33%BeatN/AN/AN/AMay 12, 2022$53.94M
    Dec 31, 2021-$0.17-$0.26N/A+34.62%BeatN/AN/AN/AMar 14, 2022$57.80M
    Sep 30, 2021-$16.06-$5.28N/A-204.17%MissN/AN/AN/ANov 15, 2021$43.18M
    Jun 30, 2021-$0.21N/AN/AN/AN/AN/AN/AN/AJul 21, 2021$47.02M
    Mar 31, 2021-$1.06N/AN/AN/AN/AN/AN/AN/AMay 24, 2021$64.20M
    Dec 31, 2020$0.00N/AN/AN/AN/AN/AN/AN/AMar 30, 2021$63.96M
    Sep 30, 2020Not reportedN/AN/AN/ANot reportedN/AN/AN/ANov 16, 2020$38.61M
    Last 25 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $1.40, up 470.7% from the year before. It was $0.00 for the year ended Dec 31, 2020, the oldest of the 6 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$1.40+470.7%
    Dec 31, 2024$0.25N/A
    Dec 31, 2023-$6.18N/A
    Dec 31, 2022-$22.86N/A
    Dec 31, 2021-$17.50N/A
    Dec 31, 2020$0.00N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 7,200 words across 13 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20267,23713
    2026Q2Jun 30, 20265,83613
    2026Q1Mar 31, 20267,59313
    2025Q4Dec 31, 20257,78514
    2025Q3Sep 30, 202510,20313
    2025Q2Jun 30, 20257,85211
    2025Q1Mar 31, 20255,4788
    2024Q4Dec 31, 20246,45910

    2026Q3 Earnings Call

    Opening remarks

    Sabrina Dunbar Investor Relations Thank you, operator, and thank you, everyone, for joining us today. On the call, we have Katherine Stueland, Chief Executive Officer; Kevin Feeley, Chief Financial Officer; and Mark Gardner, President. Earlier today, GeneDx released financial results for the third quarter ended September 30, 2026. Before we begin, please take note of our cautionary statement. We may make forward-looking statements on today's call, including about our business plans, 2026 guidance, and outlook. Forward-looking statements inherently involve risks and uncertainties and only reflect our view as of today, November 9, and we are under no obligation to update them. When discussing our results, we refer to non-GAAP measures, which exclude certain items from reported results. Please refer to our third quarter 2026 earnings release and slides available at ir.genedx.com for definitions and reconciliations of non-GAAP measures and additional information regarding our results. Additionally, please refer to our most recent annual and quarterly filings with the SEC for a discussion of factors that could cause actual results to materially differ from forward-looking statements. With that, I'll turn the call over to Katherine.

    Katherine Stueland CEO Thanks, Sabrina, and good afternoon, everyone. Our Q3 results reflect profitable execution in a growing market. As we first shared in May, we've organized our business around three key imperatives, and in Q3, we made concerted progress on each of them. First and foremost, optimizing unit economics; second, growing utilization; and third, delivering leading products at unmatched scale, all while managing capital responsibly. Today, I'll discuss the highlights of our quarter. Mark will provide a deeper dive on our RCM and commercial initiatives, and Kevin will walk us through the financials. In the third quarter, we reported $123.1 million in total revenue, expanded adjusted gross margin to 72%, generated adjusted net income of $8.6 million, and resulted over 32,100 exome and genome tests. In Q2, we shared that RCM was our number one priority, and we're pleased with the progress we saw here. Our average reimbursement rate increased approximately 5% sequentially, reflecting both improved genome collections and mix shift into our exome line. As we prioritize profitable growth, we are raising gross margin and net income guidance and reaffirming our full-year total revenue guidance. To that end, in Q3, we aligned genome testing workflows to collect more payer-required documentation before testing begins in the lab. We evaluated the potential effects on ARR, volume, and total revenue and deliberately prioritized a more sustainable path to payment, leading to a sequential step-up in ARR. As we implement these processes and educate clinicians on payer requirements, we are adjusting our volume expectations to give these workflows more time to mature.

    Frequently Asked Questions About WGS

    When is GeneDx Holdings's next earnings date?

    GeneDx Holdings's next earnings report is confirmed for Feb 22, 2027, after the close.

    Did WGS beat earnings estimates last quarter?

    Yes. GeneDx Holdings reported EPS of $0.28 for the quarter ended Sep 30, 2026, above the $0.07 estimate, a 300.00% surprise.

    What EPS do analysts expect from WGS next quarter?

    The consensus EPS estimate for GeneDx Holdings for the quarter ending Dec 31, 2026 is $0.41 from 9 analysts, with estimates from $0.37 to $0.53.

    How often does WGS beat earnings estimates?

    GeneDx Holdings beat the EPS estimate in 7 of the last 8 quarters, with an average surprise of +130.31%.

    Does WGS report before or after the market opens?

    GeneDx Holdings is confirmed to report on Feb 22, 2027, after the market closes.